Professional background

Dr Michelagnoli is a trained paediatrician with sub-specialist recognition in paediatric oncology. Her cancer training was carried out in the Yorkshire Regional Department of Paediatric Oncology and haematology. She currently works within the children's and young people cancer service at University College Hospital (CYPCS), site-specialising within the sarcoma service.

Dr Michelagnoli completed her MD (University of Leeds) at the Candlelighter's laboratory (CRUK, Leeds) in the application of molecular diagnostics in rhabdomyosarcoma.

She is chair of the service development group for Teenage and Young Adults with Cancer (TYAC) group - a professional group for specialists in young people's cancer care and she regularly teaches and lectures on the management of sarcomas in children and adolescents, as well as generic lecturing on aspects of adolescent cancer care.

Research interests

  • Bone tumours
  • Rhabdomyosarcoma
  • Fibromatosis
  • Bone presentations of LCH

Dr Michelagnoli is actively involved in coordinating sarcoma research at a national level as a member of the CCLG Sarcoma working Group, and is a member of the Connective Tissue Oncology Society.


Feltbower RG, Kinsey SE, Richards M, Shenton G, Michelagnoli MP, McKinney PA.  Survival following relapse in childhood haematological malignancies diagnosed in 1974 – 2003 in Yorkshire, UK. Br J Cancer.  2007 Apr 10;96(7): 1147-52

McTiernon A, Cassoni A, Driver D, Michelagnoli M, Kilby A, Whelan J.  Improving outcomes after relapse in Ewing’s sarcoma: Analysis of 11 patients from a single institution. Sarcoma. 2206:83548.  Epub 2006 Nov 6

McTiernon A, Driver D, Michelagnoli M, Kilby A, Whelan J.  High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours.  Annals of oncology 2006 Jun 16

Anne McTiernan, Tim Meyer, Maria P. Michelagnoli, Ian Lewis, Jeremy S. Whelan. A Phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.  Pediatric Blood & Cancer 2005 Oct 3 [Epub ahead of print]

Michelagnoli MP, Pritchard J, Phillips MB.  Adolescent oncology- a Homeland for the “Lost tribe” European Journal of Cancer 2003 Dec; 39 (18): 2571-2572

Strauss SJ, McTiernon A, Driver D, Hall-Craggs M, Sandison A, Cassoni A, Kilby a, Michelagnoli M, Pringle J, Cobb J, Briggs T, Cannon S, Witt J, Whelan JS.  Single Centre Experience of a New Intensive Induction Therapy for Ewing's Family of Tumors: Feasibility, Toxicity, and Stem Cell Mobilisation Properties.  Journal of Clinical Oncology  2003 Aug; 21 (15): 2974-2981

Michelagnoli, M.P., Burchill, S.A., Cullinane, C, Selby, P.J., and Lewis, I.J. Myogenin - a more specific target for RT-PCR detection of rhabdomyosarcoma that MyoD1.  Medical and Pediatric Oncology 2003  40 : 1-8 .
Michelagnoli MP and Viner R Commentary.The adolescent with cancer.  R.D.Barr European Journal of Cancer 2001 Aug. 37 (12):1527-1530

Michelagnoli MP, Lewis IJ, Gattamaneni HR, Bailey CC and Lashford L.  Ifosfamide and Etoposide alternating with high dose methotrexate: Evaluation of an alternative regimen for the treatment of poor risk osteosarcoma. Br J Cancer 1999 Mar;79(7-8):1174-8

Lennard L, Lewis LJ, Michelagnoli MP and Lilleyman JS.  Thiopurine Methyltransferase Deficiency in Childhood Lymphoblastic Leukaemia : 6-Mercaptopurine Dosage strategies. Medical and Pediatric Oncology 29:252-255 (1997)

Michelagnoli MP, Bailey CC, Wilson I, Livinston J, Kinsey SE.  Case report : Potential salvage therapy for inadvertent intrathecal administration of vincristine. British Journal of Haematology  99:364-367 (1997)